HC Wainwright reaffirmed their buy rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH - Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $60.00 target price on the stock.
Other research analysts have also issued research reports about the stock. Robert W. Baird initiated coverage on shares of Longboard Pharmaceuticals in a research note on Wednesday, May 1st. They set an outperform rating and a $36.00 price target on the stock. Cantor Fitzgerald restated an overweight rating and set a $60.00 price target on shares of Longboard Pharmaceuticals in a research note on Friday. Wedbush upped their price target on shares of Longboard Pharmaceuticals from $32.00 to $34.00 and gave the company an outperform rating in a research note on Friday. Finally, Citigroup initiated coverage on shares of Longboard Pharmaceuticals in a research note on Friday, February 16th. They set a buy rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Longboard Pharmaceuticals presently has an average rating of Buy and an average target price of $43.67.
Read Our Latest Research Report on LBPH
Longboard Pharmaceuticals Stock Up 7.0 %
Shares of NASDAQ LBPH traded up $1.45 during trading hours on Tuesday, hitting $22.05. 316,024 shares of the stock were exchanged, compared to its average volume of 1,187,885. The company has a market cap of $794.06 million, a PE ratio of -9.84 and a beta of 1.25. The firm has a fifty day moving average price of $20.03 and a 200-day moving average price of $15.23. Longboard Pharmaceuticals has a 12 month low of $3.60 and a 12 month high of $28.15.
Longboard Pharmaceuticals (NASDAQ:LBPH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). As a group, equities analysts anticipate that Longboard Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.
Institutional Trading of Longboard Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Longboard Pharmaceuticals during the first quarter worth $132,000. Bourgeon Capital Management LLC purchased a new stake in Longboard Pharmaceuticals during the third quarter worth $39,000. Denali Advisors LLC purchased a new stake in Longboard Pharmaceuticals during the first quarter worth $201,000. Quantbot Technologies LP purchased a new stake in Longboard Pharmaceuticals during the first quarter worth $310,000. Finally, Sei Investments Co. purchased a new stake in Longboard Pharmaceuticals during the first quarter worth $429,000. Institutional investors and hedge funds own 63.28% of the company's stock.
About Longboard Pharmaceuticals
(
Get Free Report)
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
Read More
Before you consider Longboard Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Longboard Pharmaceuticals wasn't on the list.
While Longboard Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
